DRIVE-FORWARD and DRIVE-AHEAD: Safety and Efficacy of Doravirine in Treatment-Naive Adults at 4 Yr

October 27-30, 2021; London, United Kingdom
In combined analysis of open-label extension, maintenance of virologic suppression was demonstrated through 192 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 185 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Commentary from Dr Jason Halperin on the use of 2-drug ART for rapid start, from Clinical Care Options (CCO)

Jason Halperin, MD, MPH Released: November 29, 2021

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Prof. Don Smith addresses what healthcare professionals in Australia need to know about long-acting antiretroviral agents, from Clinical Care Options (CCO)

Prof. Don Smith Released: November 23, 2021

Dr Roger Bedimo discusses the need for prophylaxis for Pneumocystis jirovecii pneumonia in virologically suppressed patients, from Clinical Care Options (CCO)

Roger Bedimo, MD, MS, FACP Released: November 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue